Metabolism News and Research

Latest Metabolism News and Research

ARIAD to complete its Phase 3 SUCCEED trial following DMS recommendation

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to full patient enrollment and completion.

14 Sep 2009

Multi-topic, hour-long series hosted by a cardiac surgeon premiers today

"The Dr. Oz Show," a high octane, multi-topic hour-long series hosted by trusted health expert, best-selling author, and world-renowned cardiac surgeon Dr. Mehmet Oz, premieres in syndication today (check local listings). Episodes airing during its premiere week feature two of the recently announced "Core Team Oz" guest contributors, fashion and style expert Tim Gunn ("Project Runway") and fitness specialist Bob Harper ("The Biggest Loser"). Also debuting this week as a member of Core Team Oz is "America's vet," Dr. Marty Becker, the popular author and regular veterinary contributor on ABC-TV's "Good Morning America."

14 Sep 2009

Centre of consciousness may lead to new coma treatments

A new understanding of how anesthesia and anesthesia-like states are controlled in the brain opens the door to possible new future treatments of various states of loss of consciousness, such as reversible coma, according to Hebrew University of Jerusalem scientists.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

Newly discovered molecular circuit helps maintain proper body metabolism

Researchers at the University of Pennsylvania School of Medicine have discovered a molecular circuit involving heme that helps maintain proper metabolism in the body, providing new insights into metabolic disorders such as obesity and diabetes.

14 Sep 2009

Reme-Flu secured as trade name for Nuvilex's homeopathic flu remedy

Nuvilex, Inc., announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the company that Reme-Flu has been secured as the trade name for its homeopathic remedy for helping to prevent and treat flu-like symptoms resulting from influenza, including swine flu.

14 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

Enlarged fat cells and waist-to-height ratios can cause diabetes in women

When it comes to assessing risk for type 2 diabetes, not only do waistlines matter to women, but so does the size of their fat cells. This new discovery by a team of Swedish researchers was just published online in the FASEB Journal (http://www.fasebj.org) and helps explain why some women of normal weight develop type 2 diabetes, despite not having any known risk factors.

11 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009

Nuvilex and Legacy Biotechnologies to develop natural remedies for flu- type symptoms

Nuvilex, Inc., announces today that it has entered into a Joint Venture Agreement with Legacy Biotechnologies, Inc., a private company based in Tampa, Florida, to develop and market all natural remedies for symptoms of broad spectrum flu viruses.

11 Sep 2009

Natural plant hormone can help eliminate pesticide residues in food crops

Scientists in China are reporting the "intriguing" discovery that a natural plant hormone, applied to crops, can help plants eliminate residues of certain pesticides. The study is scheduled for the Sept. 23 issue of ACS' Journal of Agricultural and Food Chemistry, a bi-weekly publication.

10 Sep 2009

ADDF's grant to Abiant for developing accurate imaging diagnostic approach

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $200,000 to Abiant, Inc. (Deerfield, IL), for the development of a highly accurate imaging diagnostic for Alzheimer's Disease.

9 Sep 2009

New findings may help identify treatments for diabetes and hyperinsulinemia

By investigating a rare and severe form of diabetes in children, University of Iowa researchers have discovered a new molecular mechanism that regulates specialized pancreatic cells and insulin secretion. The mechanism involves a protein called ankyrin, which UI researchers previously linked to potentially fatal human heart arrhythmias.

9 Sep 2009

Roche RTS Protein Expression portfolio transferred to RiNA GmbH

Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009.

8 Sep 2009

eBioscience Corporation announces the acquisition of NatuTec GmbH

eBioscience Corporation, a leading global provider of innovative, high-quality cell analysis reagents announced today the acquisition of NatuTec GmbH, a leading distributor of high-quality biological research reagents located in Frankfurt am Main, Germany.

8 Sep 2009

Proteostasis Therapeutics to use GeneGo's MetaCore integrated software

GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body's Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases.

8 Sep 2009